Wells Fargo analyst Mohit Bansal raised the firm’s price target on Bristol Myers (BMY) to $60 from $55 and keeps an Equal Weight rating on the shares. The firm sees upside to 2026 guidance as growth portfolio could outperform mid-single-digit guidance due to continued growth from certain products. With guide out of the way, investors can focus on pipeline with readouts for CelMoDs, LPA1, Milvexian, and Cobenfy in 2026, Wells adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
- Bristol-Myers Squibb Bets On New Growth Engines
- Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
- Truist incrementally positive on Bristol Myers after Bayer asundexian data
- TrumpRx website using technology from GoodRx, STAT says